Date: 2014-07-22
Type of information: Preclinical data
phase: preclinical
Announcement: preclinical data
Company: Glide Pharma (UK)
Product: octreotide acetate
Action mechanism:
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: * On July 22, 2014, Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). Based on these results, the company intends to transfer the formulation production process to a contract manufacturing organisation , and to advance Glide octreotide delivered with the needle-free Glide solid dose injector (SDI®) into clinical trials in 2015. The pre-clinical study compared the pharmacokinetic profile of the most widely used clinical dose of Sandostatin (100 mcg) with that of Glide\'s octreotide solid dose formulation. The results demonstrated that there was no statistical difference between the two profiles.
